CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation. Leronlimab is a humanized monoclonal antibody that is a once-a-week subcutaneous injection that can also be administered intravenously. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor. This mechanism of action of binding competitively to the CCR5 receptor differentiates leronlimab from all other CCR5 antagonists.
我們正在追蹤 CytoDyn 的市場擴張
CytoDyn 的國際擴張與競爭對手的比較
CytoDyn你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 CytoDyn你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
CytoDyn 為三陰性乳腺癌患者啟動擴大使用計劃，推進首創人源化單克隆抗體 leronlimab 的研發。
CytoDyn公佈leronlimab治療轉移性三陰性乳腺癌患者的存活數據令人鼓舞，顯示潛在治療效益。
CytoDyn已完成其第二階段轉移性結直腸癌研究的招募,在美國七個臨床地點招募了超過60名患者。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 CytoDyn 業務、市場及增長訊號的快速解答。
